These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8573543)

  • 1. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1995 Jul; 6(6):613-5. PubMed ID: 8573543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; Vecht C; de Boer-Dennert M; Stoter G; Verweij J
    Eur J Cancer; 1996 Oct; 32A(11):2026-8. PubMed ID: 8943692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
    Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
    Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
    Purohit A; Moreau L; Dietemann A; Seibert R; Pauli G; Wihlm JM; Quoix E
    Lung Cancer; 1998 Nov; 22(2):119-25. PubMed ID: 10022219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
    Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
    Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly high-dose cisplatin in malignant pleural mesothelioma.
    Planting AS; Schellens JH; Goey SH; van der Burg ME; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1994 Apr; 5(4):373-4. PubMed ID: 8075038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
    Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
    Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.
    Planting AS; van der Burg ME; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Br J Cancer; 1996 May; 73(10):1265-7. PubMed ID: 8630290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
    White SC; Anderson H; Jayson GC; Ashcroft L; Ranson M; Thatcher N
    Ann Oncol; 2000 Feb; 11(2):201-6. PubMed ID: 10761756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer EA; Evans WK; Murray N; Kocha W; Wierzbicki R; Wilson K
    Invest New Drugs; 1988 Dec; 6(4):327-9. PubMed ID: 3229945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
    Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G
    Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
    Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
    Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.